603259 药明康德
2021/03 - 三个月
人民幣(K¥)
与去年同期
比较
2020/12
人民幣(K¥)
2019/12
人民幣(K¥)
2018/12
人民幣(K¥)
2017/12
人民幣(K¥)
营业总收入4,950,48055.31%16,535,43112,872,2069,613,6847,765,260
减:营业总成本3,996,29950.23%13,928,30410,421,6957,810,9666,428,780
    其中:营业成本3,113,89249.06%10,253,2767,858,2995,820,9834,516,794
               财务费用32,378-173.04%519,80423,96156,210184,463
               资产减值损失3,549-686.85%(62,642)(1,433)(2,011)140,956
公允价值变动收益211,808-376.83%52,271(259,257)606,437678
投资收益483,773-792.76%606,23147,54779,63639,794
    其中:对联营企业和合营企业的投资收益(28,416)-66.08%(90,752)(20,717)76,830(48,640)
营业利润1,697,540303.94%3,389,4852,340,9242,584,7031,460,595
利润总额1,695,894307.83%3,369,3762,336,9692,580,8241,592,620
减:所得税费用188,78970.50%383,126425,559247,143295,900
净利润1,507,105393.96%2,986,2501,911,4092,333,6811,296,721
减:非控股权益7,299253.35%26,01556,85873,15869,627
股东净利润1,499,805394.92%2,960,2351,854,5512,260,5231,227,093

市场价值指针
每股收益 (元) *0.620376.92%1.2700.8101.5901.310
每股派息 (元) *----0.3630.3370.580--
每股净资产 (元) *14.40333.97%13.30810.49015.1866.763
审计意见 #--标准无保留意见标准无保留意见标准无保留意见--
回页顶
备注: *未调整数据
#只提供简体内容